115 related articles for article (PubMed ID: 28092860)
1. Design, synthesis and biological evaluation of quinazoline-phosphoramidate mustard conjugates as anticancer drugs.
Lin S; Li Y; Zheng Y; Luo L; Sun Q; Ge Z; Cheng T; Li R
Eur J Med Chem; 2017 Feb; 127():442-458. PubMed ID: 28092860
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of indolequinone phosphoramidate prodrugs targeted to DT-diaphorase.
Hernick M; Flader C; Borch RF
J Med Chem; 2002 Aug; 45(16):3540-8. PubMed ID: 12139465
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of peptide conjugates of phosphoramide mustard as prodrugs activated by prostate-specific antigen.
Wu X; Hu L
Bioorg Med Chem; 2016 Jun; 24(12):2697-706. PubMed ID: 27156193
[TBL] [Abstract][Full Text] [Related]
4. Chemically stable, lipophilic prodrugs of phosphoramide mustard as potential anticancer agents.
Kwon CH; Moon KY; Baturay N; Shirota FN
J Med Chem; 1991 Feb; 34(2):588-92. PubMed ID: 1995881
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and antitumor evaluation of phenyl N-mustard-quinazoline conjugates.
Marvania B; Lee PC; Chaniyara R; Dong H; Suman S; Kakadiya R; Chou TC; Lee TC; Shah A; Su TL
Bioorg Med Chem; 2011 Mar; 19(6):1987-98. PubMed ID: 21356592
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of targeted hypoxia-activated prodrugs applied to chondrosarcoma chemotherapy.
Gerard Y; Voissière A; Peyrode C; Galmier MJ; Maubert E; Ghedira D; Tarrit S; Gaumet V; Canitrot D; Miot-Noirault E; Chezal JM; Weber V
Bioorg Chem; 2020 May; 98():103747. PubMed ID: 32208207
[TBL] [Abstract][Full Text] [Related]
7. Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines.
Jain M; Fan J; Baturay NZ; Kwon CH
J Med Chem; 2004 Jul; 47(15):3843-52. PubMed ID: 15239662
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
Jiang Y; Han J; Yu C; Vass SO; Searle PF; Browne P; Knox RJ; Hu L
J Med Chem; 2006 Jul; 49(14):4333-43. PubMed ID: 16821793
[TBL] [Abstract][Full Text] [Related]
9. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of novel quinazoline nitrogen mustard derivatives as potential therapeutic agents for cancer.
Li S; Wang X; He Y; Zhao M; Chen Y; Xu J; Feng M; Chang J; Ning H; Qi C
Eur J Med Chem; 2013 Sep; 67():293-301. PubMed ID: 23871909
[TBL] [Abstract][Full Text] [Related]
12. Discovery of new quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors and their anticancer activities - Part 1.
Das D; Xie L; Wang J; Xu X; Zhang Z; Shi J; Le X; Hong J
Bioorg Med Chem Lett; 2019 Feb; 29(4):591-596. PubMed ID: 30600209
[TBL] [Abstract][Full Text] [Related]
13. Novel Sophoridine Derivatives Bearing Phosphoramide Mustard Moiety Exhibit Potent Antitumor Activities In Vitro and In Vivo.
Li D; Dai L; Zhao X; Zhi S; Shen H; Yang Z
Molecules; 2018 Aug; 23(8):. PubMed ID: 30082625
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
Cai X; Zhai HX; Wang J; Forrester J; Qu H; Yin L; Lai CJ; Bao R; Qian C
J Med Chem; 2010 Mar; 53(5):2000-9. PubMed ID: 20143778
[TBL] [Abstract][Full Text] [Related]
15. Acyloxymethyl esters of isophosphoramide mustard as new anticancer prodrugs.
Cytarska J; Misiura K; Filip-Psurska B; Wietrzyk J
Acta Pol Pharm; 2013; 70(3):481-7. PubMed ID: 23757939
[TBL] [Abstract][Full Text] [Related]
16. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
[TBL] [Abstract][Full Text] [Related]
17. Design and Synthesis of 4-substituted Quinazolines as Potent EGFR Inhibitors with Anti-breast Cancer Activity.
Ahmed MF; Magdy N
Anticancer Agents Med Chem; 2017; 17(6):832-838. PubMed ID: 27671305
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of some novel substituted quinazolines as antitumor agents.
Alanazi AM; Abdel-Aziz AA; Al-Suwaidan IA; Abdel-Hamide SG; Shawer TZ; El-Azab AS
Eur J Med Chem; 2014 May; 79():446-54. PubMed ID: 24763265
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of novel water-soluble N-mustards as potential anticancer agents.
Kapuriya N; Kakadiya R; Dong H; Kumar A; Lee PC; Zhang X; Chou TC; Lee TC; Chen CH; Lam K; Marvania B; Shah A; Su TL
Bioorg Med Chem; 2011 Jan; 19(1):471-85. PubMed ID: 21106377
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo[4,5-g]quinazolin-2(1H)-one scaffold.
Yin S; Tang C; Wang B; Zhang Y; Zhou L; Xue L; Zhang C
Eur J Med Chem; 2016 Sep; 120():26-36. PubMed ID: 27187856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
